GlaxoSmithKline plc Company Profile (LON:GSK)

About GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:GSK
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: £79.06 billion
  • Outstanding Shares: 4,886,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 1,616.19
  • 200 Day Moving Avg: GBX 1,587.57
  • 52 Week Range: GBX 1,363 - GBX 1,745.56
  • Trailing P/E Ratio: 47.92
  • P/E Growth: 2.05
Sales & Book Value:
  • Annual Revenue: £29.04 billion
  • Price / Sales: 2.72
  • Book Value: GBX 0.35 per share
  • Price / Book: 46.23
  • Dividend Yield: 4.8%
  • EBIDTA: £7.3 billion
  • Average Volume: 8.98 million shs.

Frequently Asked Questions for GlaxoSmithKline plc (LON:GSK)

What is GlaxoSmithKline plc's stock symbol?

GlaxoSmithKline plc trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

How often does GlaxoSmithKline plc pay dividends? What is the dividend yield for GlaxoSmithKline plc?

GlaxoSmithKline plc declared a dividend on Wednesday, April 26th. Stockholders of record on Thursday, May 11th will be given a dividend of GBX 19 per share on Thursday, July 13th. This represents a dividend yield of 1.21%. The ex-dividend date is Thursday, May 11th. The official announcement can be seen at this link. View GlaxoSmithKline plc's Dividend History.

When will GlaxoSmithKline plc make its next earnings announcement?

GlaxoSmithKline plc is scheduled to release their next quarterly earnings announcement on Monday, July, 24th 2017. View Earnings Estimates for GlaxoSmithKline plc.

Where is GlaxoSmithKline plc's stock going? Where will GlaxoSmithKline plc's stock price be in 2017?

23 brokers have issued twelve-month price objectives for GlaxoSmithKline plc's stock. Their predictions range from GBX 1,300 to GBX 1,970. On average, they anticipate GlaxoSmithKline plc's stock price to reach GBX 1,743.36 in the next twelve months. View Analyst Ratings for GlaxoSmithKline plc.

Who are some of GlaxoSmithKline plc's key competitors?

How do I buy GlaxoSmithKline plc stock?

Shares of GlaxoSmithKline plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of GlaxoSmithKline plc stock cost?

One share of GlaxoSmithKline plc stock can currently be purchased for approximately GBX 1,618.

Analyst Ratings

Consensus Ratings for GlaxoSmithKline plc (LON:GSK) (?)
Ratings Breakdown: 3 Sell Ratings, 12 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: GBX 1,743.36

Analysts' Ratings History for GlaxoSmithKline plc (LON:GSK)
DateFirmActionRatingPrice TargetDetails
5/23/2017Deutsche Bank AGReiterated RatingHoldView Rating Details
5/20/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,750View Rating Details
5/20/2017Morgan StanleySet Price TargetNeutralGBX 1,700View Rating Details
5/12/2017Barclays PLCReiterated RatingEqual weightView Rating Details
5/12/2017Jefferies Group LLCReiterated RatingBuyGBX 1,800View Rating Details
5/11/2017Shore CapitalReiterated RatingHoldView Rating Details
5/5/2017Berenberg BankSet Price TargetNeutralGBX 1,850View Rating Details
5/5/2017Liberum CapitalReiterated RatingBuyGBX 1,900View Rating Details
5/5/2017HSBC Holdings plcReiterated RatingBuyGBX 1,970View Rating Details
4/27/2017Goldman Sachs Group IncSet Price TargetBuyGBX 1,900View Rating Details
4/27/2017Credit Suisse Group AGReiterated RatingNeutralGBX 1,750View Rating Details
4/27/2017Beaufort SecuritiesReiterated RatingBuyGBX 1,750View Rating Details
4/27/2017Kepler Capital MarketsReiterated RatingReduceGBX 1,500View Rating Details
4/3/2017BNP ParibasReiterated RatingUnderperformGBX 1,520View Rating Details
3/23/2017Societe GeneraleReiterated RatingSellGBX 1,300View Rating Details
1/9/2017Bryan, Garnier & CoReiterated RatingBuyGBX 1,850View Rating Details
11/7/2016Citigroup IncReiterated RatingBuyView Rating Details
10/27/2016NatixisReiterated RatingNeutralGBX 1,750View Rating Details
10/20/2016InvestecInitiated CoverageBuyGBX 1,925View Rating Details
10/19/2016Sanford C. BernsteinSet Price TargetNeutralGBX 1,834View Rating Details
8/4/2016Independent Research GmbHSet Price TargetNeutralGBX 1,800View Rating Details
7/27/2016S&P Global IncSet Price TargetNeutralGBX 1,650View Rating Details
7/7/2016Canaccord GenuityReiterated RatingHoldGBX 1,785View Rating Details
3/10/2016AlphaValueReiterated RatingAddGBX 1,536View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 1,530View Rating Details
1/28/2016Leerink SwannReiterated RatingMarket PerformGBX 1,565View Rating Details
11/17/2015JP Morgan CazenoveReiterated RatingNeutralGBX 1,370View Rating Details
11/6/2015Oddo SecuritiesReiterated RatingReduceGBX 1,360View Rating Details
9/7/2015Bank of America CorpUpgradeNeutralView Rating Details
6/9/2015Cenkos Securities LtdReiterated RatingBuyGBX 1,643View Rating Details
(Data available from 5/25/2015 forward)


Earnings History for GlaxoSmithKline plc (LON:GSK)
No earnings announcements for this company have been tracked by


Earnings Estimates for GlaxoSmithKline plc (LON:GSK)
Current Year EPS Consensus Estimate: $110.64 EPS


Dividend History by Quarter for GlaxoSmithKline plc (LON:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/26/2017GBX 191.21%5/11/20175/11/20177/13/2017
2/8/2017GBX 231.47%2/23/20172/23/20174/13/2017
10/26/2016GBX 191.17%11/3/201611/3/20161/12/2017
7/27/2016GBX 191.12%8/11/20168/11/201610/13/2016
4/27/2016GBX 191.28%5/12/20165/12/20167/14/2016
10/28/2015GBX 191.34%11/12/201511/12/20151/14/2016
10/28/2015GBX 201.34%2/18/20162/18/20164/14/2016
7/29/2015GBX 191.38%8/13/20158/13/201510/1/2015
5/6/2015GBX 191.25%5/14/20155/14/20157/9/2015
2/4/2015GBX 231.56%2/19/20152/19/20154/9/2015
10/22/2014GBX 191.37%11/6/201411/6/20141/8/2015
7/23/2014GBX 191.28%8/6/20148/6/201410/2/2014
4/30/2014GBX 191.17%5/14/20145/14/20147/10/2014
2/5/2014GBX 231.36%2/19/20142/19/20144/10/2014
10/23/2013GBX 191.15%11/13/201311/13/20131/9/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for GlaxoSmithKline plc (LON:GSK)
Insider Trades by Quarter for GlaxoSmithKline plc (LON:GSK)
Insider Trades by Quarter for GlaxoSmithKline plc (LON:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Patrick VallanceInsiderBuy7GBX 1,615£113.05
4/26/2017Vivienne CoxInsiderBuy335GBX 1,583£5,303.05
4/18/2017Emma WalmsleyInsiderBuy83GBX 1,647£1,367.01
4/13/2017Dominic RedfernInsiderBuy230GBX 1,639£3,769.70
3/9/2017Sir Andrew P WittyInsiderBuy7GBX 1,673£117.11
3/7/2017Moncef SlaouiInsiderBuy56GBX 2,072£1,160.32
2/22/2017Simon DingemansInsiderSell3,589GBX 1,640£58,859.60
2/20/2017Sir Andrew P WittyInsiderSell10,633GBX 1,634£173,743.22
2/16/2017Patrick VallanceInsiderSell32,996GBX 1,624£535,855.04
2/9/2017Victoria WhyteInsiderSell4,820GBX 1,576£75,963.20
2/8/2017Vivienne CoxInsiderBuy342GBX 1,555£5,318.10
1/11/2017Simon DingemansInsiderBuy8GBX 1,596£127.68
1/9/2017Moncef SlaouiInsiderBuy58GBX 1,972£1,143.76
12/9/2016Sir Andrew P WittyInsiderBuy8GBX 1,478£118.24
11/9/2016Victoria WhyteInsiderBuy8GBX 1,593£127.44
11/3/2016Moncef SlaouiInsiderBuy6GBX 1,937£116.22
10/27/2016Sir Andrew P WittyInsiderSell10,000GBX 1,636£163,600
10/26/2016Manvinder Singh BangaInsiderBuy1,750GBX 1,643£28,752.50
10/11/2016Simon DingemansInsiderBuy7GBX 1,728£120.96
10/7/2016Moncef SlaouiInsiderBuy4GBX 2,148GBX 8,592
9/22/2016Moncef SlaouiInsiderBuy2GBX 2,179GBX 4,358
9/9/2016Witty,Sir Andrew PInsiderBuy8GBX 1,616£129.28
8/12/2016Slaoui,MoncefInsiderBuy28GBX 2,208£618.24
8/9/2016Dingemans,SimonInsiderBuy8GBX 1,680£134.40
7/27/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,693£169,300
7/11/2016Witty,Sir Andrew PInsiderBuy7GBX 1,671£116.97
7/8/2016Slaoui,MoncefInsiderBuy4GBX 2,169GBX 8,676
7/1/2016Cartwright,StaceyInsiderBuy461GBX 1,559£7,186.99
6/9/2016Dingemans,SimonInsiderBuy9GBX 1,441£129.69
5/20/2016Slaoui,MoncefInsiderBuy14GBX 2,100£294
5/12/2016Slaoui,MoncefInsiderBuy24GBX 2,103£504.72
5/11/2016Witty,Sir Andrew PInsiderBuy8GBX 1,476£118.08
4/28/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,475£147,500
4/14/2016Slaoui,MoncefInsiderBuy495GBX 2,156£10,672.20
3/31/2016Anderson,Sir RoyInsiderBuy511GBX 1,405£7,179.55
3/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,404£126.36
2/15/2016Dingemans,SimonInsiderSell39,987GBX 1,406£562,217.22
2/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
1/28/2016Dingemans,SimonInsiderBuy684GBX 1,381£9,446.04
1/14/2016Witty,Sir Andrew PInsiderBuy43GBX 1,369£588.67
1/12/2016Dingemans,SimonInsiderBuy9GBX 1,359£122.31
12/9/2015Dingemans,SimonInsiderBuy9GBX 1,325£119.25
11/10/2015Dingemans,SimonInsiderBuy9GBX 1,366£122.94
10/12/2015Dingemans,SimonInsiderBuy10GBX 1,307£130.70
10/1/2015Rohner,UrsInsiderBuy525GBX 1,251£6,567.75
9/10/2015Witty,Sir Andrew PInsiderBuy10GBX 1,318£131.80
8/12/2015Dingemans,SimonInsiderBuy8GBX 1,443£115.44
7/10/2015Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
7/1/2015Wijers,HansInsiderBuy534GBX 13.45GBX 7,182.30
3/31/2015Sir Christopher GentInsiderBuy3,991GBX 1,566£62,499.06
3/9/2015Moncef SlaouiInsiderSell22,274GBX 1,544£343,910.56
2/18/2015Moncef SlaouiInsiderSell1,580GBX 1,553£24,537.40
2/13/2015Simon DingemansInsiderSell12,605GBX 1,543.12£194,510.28
(Data available from 1/1/2013 forward)


Headline Trends for GlaxoSmithKline plc (LON:GSK)
Latest Headlines for GlaxoSmithKline plc (LON:GSK)
DateHeadline logoDeutsche Bank AG Reiterates "GBX 1,720" Price Target for GlaxoSmithKline plc (GSK) - May 21 at 1:08 PM logoGlaxoSmithKline plc (GSK) PT Set at GBX 1,700 by Morgan Stanley - May 21 at 11:52 AM logoGlaxoSmithKline plc (GSK) Given a GBX 1,750 Price Target by JPMorgan Chase & Co. Analysts - May 21 at 11:20 AM logoIonis (IONS) Stock Falls Despite Positive Inotersen Data - May 16 at 10:29 PM logoShould you follow Neil Woodford and dump GlaxoSmithKline plc? - May 15 at 11:13 AM logoGlaxoSmithKline plc (GSK) Given Average Rating of "Hold" by Analysts - May 15 at 10:54 AM logoGlaxoSmithKline plc (GSK) Rating Reiterated by Shore Capital - May 14 at 11:28 AM logoGlaxoSmithKline plc (GSK) Rating Reiterated by Jefferies Group LLC - May 13 at 2:05 PM logoGlaxoSmithKline plc (GSK) Receives "Equal weight" Rating from Barclays PLC - May 13 at 1:20 PM logoGlaxoSmithKline plc (GSK) PT Raised to GBX 1,750 at JPMorgan Chase & Co. - May 13 at 12:10 PM logoMorgan Stanley Analysts Give GlaxoSmithKline plc (GSK) a GBX 1,700 Price Target - May 13 at 12:10 PM logoGlaxoSmithKline Plc : GSK-GB: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 12, 2017 - May 12 at 11:14 PM logoDeutsche Bank AG Analysts Give GlaxoSmithKline plc (GSK) a GBX 1,720 Price Target - May 12 at 6:14 AM logoInsider Buying: GlaxoSmithKline plc (GSK) Insider Acquires 7 Shares of Stock - May 11 at 1:38 PM logo[$$] Trump's Pick to Lead FDA Has Backing of Big Pharma - May 9 at 12:44 PM logoHow These Healthcare Stocks are Faring? -- GlaxoSmithKline, Shire, Perrigo, and BioScrip - May 8 at 8:21 AM logoGlaxoSmithKline plc (GSK) Earns "Buy" Rating from HSBC Holdings plc - May 6 at 10:34 PM logoGlaxoSmithKline plc (GSK) Rating Reiterated by Liberum Capital - May 6 at 10:02 PM logoGlaxoSmithKline plc (GSK) Given a GBX 1,850 Price Target at Berenberg Bank - May 6 at 7:28 PM logoRelvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care - May 5 at 4:07 PM logoGSK 'real world' drug test has second success in asthma - May 5 at 4:07 PM logoHere's What Wiped $3 Billion Off GlaxoSmithKline's Market Cap in April - May 4 at 12:02 PM logoVivienne Cox Purchases 335 Shares of GlaxoSmithKline plc (GSK) Stock - May 1 at 7:13 AM logoGlaxoSmithKline plc (GSK) Rating Reiterated by HSBC Holdings plc - April 30 at 7:27 PM logoDeutsche Bank AG Trims GlaxoSmithKline plc (GSK) Target Price to GBX 1,700 - April 30 at 6:54 PM logoKepler Capital Markets Reaffirms "Reduce" Rating for GlaxoSmithKline plc (GSK) - April 30 at 4:59 PM logoGlaxoSmithKline plc (GSK) Price Target Lowered to GBX 1,700 at Deutsche Bank AG - April 28 at 7:10 PM logoGlaxoSmithKline plc (GSK) Given "Buy" Rating at HSBC Holdings plc - April 28 at 7:08 PM logoEdited Transcript of GSK.L earnings conference call or presentation 26-Apr-17 1:00pm GMT - April 28 at 10:26 AM logoGlaxoSmithKline plc (GSK) Rating Reiterated by Credit Suisse Group AG - April 27 at 9:24 PM logoGlaxoSmithKline plc (GSK) Given a GBX 1,900 Price Target at Goldman Sachs Group Inc - April 27 at 10:40 AM logoAstraZeneca committed to UK, despite market challenges - April 27 at 8:13 AM logoGlaxoSmithKline plc's (GSK) Buy Rating Reiterated at Beaufort Securities - April 27 at 6:24 AM logoGlaxoSmithKline Q1 Profit Surges - April 26 at 7:49 PM logoGlaxo (GSK) Beats Earnings and Revenues in Q1 - Yahoo Finance - Yahoo Finance - April 26 at 7:49 PM logoGlaxoSmithKline Plc (GSK) Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - April 26 at 7:49 PM logoGlaxoSmithKline plc (GSK) Announces Dividend of GBX 19 - April 26 at 4:18 PM logoETFs with exposure to GlaxoSmithKline Plc : April 25, 2017 - April 25 at 5:06 PM logoGlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates - April 25 at 11:02 AM logoGlaxoSmithKline’s 1Q17 Estimates: Revenues Expected to Grow - April 25 at 11:02 AM logoGlaxoSmithKline’s 1Q17 Estimates: Pharmaceuticals Segment - April 25 at 11:02 AM logoGlaxoSmithKline plc's (GSK) Hold Rating Reaffirmed at Shore Capital - April 22 at 3:27 PM logoWhat's in Store for GlaxoSmithKline (GSK) in Q1 Earnings? - Nasdaq - April 21 at 10:32 PM logoGlaxoSmithKline plc (GSK) PT Lowered to GBX 1,800 at Jefferies Group LLC - April 20 at 7:37 PM logoInsider Buying: GlaxoSmithKline plc (GSK) Insider Acquires 83 Shares of Stock - April 20 at 7:22 AM logoGlaxoSmithKline plc (GSK) Insider Purchases £3,769.70 in Stock - April 20 at 7:22 AM logoActivist Sarissa says Innoviva backed out of proxy settlement deal - April 19 at 10:28 PM logo[$$] Science looks to nucleic acids to create right genetic vaccine recipe - April 19 at 11:44 AM logo[$$] Amid vaccine debate, Italy faces return of eradicable diseases - April 19 at 11:44 AM logoWhy 'biobucks' aren't enough: Biotech stalwart stumbles despite cash promise - April 18 at 11:22 AM


Social activity is not available for this stock.


GlaxoSmithKline plc (GSK) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff